CY1110363T1 - Παραγωγα (1-4-πιπεριδινυλ)βενζιμιδαζολιου χρησιμα σαν ανταγωνιστες η3 ισταμινης - Google Patents
Παραγωγα (1-4-πιπεριδινυλ)βενζιμιδαζολιου χρησιμα σαν ανταγωνιστες η3 ισταμινηςInfo
- Publication number
- CY1110363T1 CY1110363T1 CY20081100604T CY081100604T CY1110363T1 CY 1110363 T1 CY1110363 T1 CY 1110363T1 CY 20081100604 T CY20081100604 T CY 20081100604T CY 081100604 T CY081100604 T CY 081100604T CY 1110363 T1 CY1110363 T1 CY 1110363T1
- Authority
- CY
- Cyprus
- Prior art keywords
- formula
- histamine
- antagonists
- compounds
- disclosed
- Prior art date
Links
- 239000003395 histamine H3 receptor antagonist Substances 0.000 title abstract 2
- QYCKVZZMAXDBHQ-UHFFFAOYSA-N 1-piperidin-4-ylbenzimidazole Chemical class C1CNCCC1N1C2=CC=CC=C2N=C1 QYCKVZZMAXDBHQ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 230000007815 allergy Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028735 Nasal congestion Diseases 0.000 abstract 1
- 230000008369 airway response Effects 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 208000027744 congestion Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000000938 histamine H1 antagonist Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Αποκαλύπτονται ανταγωνιστές Η3 ισταμίνης του τύπου (I) όπου το R1 προαιρετικά είναι υποκατεστημένο βενζιμιδαζολυλ ή παράγωγο αυτού, το R2 είναι προαιρετικά υποκατεστημένο αρυλ ή ετεροαρυλ, τα Μ1 και Μ2 είναι C(R3) ή Ν, το Q είναι -N(R8)-, -S- ή -Ο- και οι υπόλοιπες μεταβλητές είναι όπως ορίζονται στην περιγραφή. Επίσης αποκαλύπτονται φαρμακευτικές συνθέσεις που περιλαμβάνουν τις ενώσεις του τύπου I και μεθόδους θεραπείας διαφόρων ασθενειών ή καταστάσεων, όπως αλλεργίες, διεγειρόμενων από αλλεργία αποκρίσεων αεροδού και συμφόρησης (π.χ., ρινικής συμφόρησης) χρησιμοποιώντας τις ενώσεις του τύπου I. Επίσης αποκαλύπτονται μέθοδοι θεραπείας των εν λόγω ασθενειών ή καταστάσεων χρησιμοποιώντας τις ενώσεις του τύπου I σε συνδυασμό με ανταγωνιστή υποδοχέα H1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37373102P | 2002-04-18 | 2002-04-18 | |
| PCT/US2003/011672 WO2003088967A1 (en) | 2002-04-18 | 2003-04-16 | (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110363T1 true CY1110363T1 (el) | 2012-05-23 |
Family
ID=29251069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081100604T CY1110363T1 (el) | 2002-04-18 | 2008-06-09 | Παραγωγα (1-4-πιπεριδινυλ)βενζιμιδαζολιου χρησιμα σαν ανταγωνιστες η3 ισταμινης |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1499316B1 (el) |
| JP (1) | JP4384918B2 (el) |
| KR (1) | KR100827470B1 (el) |
| CN (1) | CN100522166C (el) |
| AR (1) | AR040405A1 (el) |
| AT (1) | ATE389406T1 (el) |
| AU (1) | AU2003223627B2 (el) |
| BR (1) | BR0309348A (el) |
| CA (1) | CA2481940A1 (el) |
| CY (1) | CY1110363T1 (el) |
| DE (1) | DE60319813T2 (el) |
| DK (1) | DK1499316T3 (el) |
| EC (1) | ECSP045367A (el) |
| ES (1) | ES2301791T3 (el) |
| HK (1) | HK1067981A1 (el) |
| IL (1) | IL164584A (el) |
| MX (1) | MXPA04010173A (el) |
| NO (1) | NO20045002L (el) |
| NZ (1) | NZ535763A (el) |
| PE (1) | PE20040684A1 (el) |
| PL (1) | PL373889A1 (el) |
| PT (1) | PT1499316E (el) |
| RU (1) | RU2323935C2 (el) |
| SI (1) | SI1499316T1 (el) |
| TW (1) | TW200306183A (el) |
| WO (1) | WO2003088967A1 (el) |
| ZA (1) | ZA200407984B (el) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4613157B2 (ja) | 2003-01-14 | 2011-01-12 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
| TW200503713A (en) | 2003-04-23 | 2005-02-01 | Glaxo Group Ltd | Novel compounds |
| EP1765327B1 (en) | 2004-06-17 | 2014-08-13 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
| WO2006038738A1 (ja) * | 2004-10-08 | 2006-04-13 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
| CN101107231A (zh) * | 2005-01-21 | 2008-01-16 | 先灵公司 | 用作组胺h3拮抗剂的咪唑和苯并咪唑衍生物 |
| CN101243072A (zh) | 2005-06-20 | 2008-08-13 | 先灵公司 | 用作组胺h3拮抗剂的哌啶衍生物 |
| JP2008543940A (ja) * | 2005-06-20 | 2008-12-04 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用な、炭素結合した置換ピペリジンおよびその誘導体 |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| JP4860700B2 (ja) * | 2005-09-20 | 2012-01-25 | シェーリング コーポレイション | ヒスタミンＨ３アンタゴニストとして有用な、１−［［１−［（２−アミノ−６−メチル−４−ピリジニル）メチル］−４−フルオロ−４−ピペリジニル］カルボニル］−４−［２−（２−ピリジニル）−３Ｈ−イミダゾ［４，５−ｂ］ピリジン−３−イル］ピペリジン |
| CN101273026A (zh) * | 2005-09-30 | 2008-09-24 | 霍夫曼-拉罗奇有限公司 | 作为mch受体拮抗剂的茚满衍生物 |
| AR058347A1 (es) | 2005-12-15 | 2008-01-30 | Cytokinetics Inc | Entidades quimias composiciones y metodos |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| US7718657B2 (en) | 2005-12-16 | 2010-05-18 | Cytokinetics, Inc. | Certain indanyl urea modulators of the cardiac sarcomere |
| WO2007078839A2 (en) | 2005-12-19 | 2007-07-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
| PE20071162A1 (es) * | 2005-12-21 | 2007-11-30 | Schering Corp | Combinacion de un antagonista/agonista inverso de h3 y un supresor del apetito |
| JP2009521448A (ja) | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ |
| AU2007204426A1 (en) * | 2006-01-13 | 2007-07-19 | F. Hoffmann-La Roche Ag | Cyclohexyl piperazinyl methanone derivatives and their use as histamine H3 receptor modulators |
| TW200813018A (en) | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| CN101809021B (zh) * | 2007-09-11 | 2013-04-24 | 雅培制药有限公司 | 八氢-吡咯并[3,4-b]吡咯n-氧化物 |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| CN102781940B (zh) | 2009-12-30 | 2016-09-07 | 艾科尔公司 | 取代的咪唑并吡啶基-氨基吡啶化合物 |
| WO2012177852A1 (en) | 2011-06-24 | 2012-12-27 | Arqule, Inc | Substituted imidazopyridinyl compounds |
| CA2837727C (en) | 2011-06-24 | 2019-12-03 | Arqule, Inc. | Substituted imidazopyridinyl-aminopyridine compounds |
| KR101127756B1 (ko) | 2011-09-02 | 2012-03-23 | 한국과학기술원 | Ｇｉｔ１ 유전자 결손 마우스 및 이를 이용한 약물 스크리닝 방법 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| JP6046646B2 (ja) | 2014-01-10 | 2016-12-21 | 信越化学工業株式会社 | オニウム塩、化学増幅型ポジ型レジスト組成物、及びパターン形成方法 |
| US10595550B2 (en) * | 2014-01-22 | 2020-03-24 | Vision Pharma, Llc | Therapeutic composition including carbonated solution |
| US10118900B2 (en) | 2015-08-25 | 2018-11-06 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as CB-1 inverse agonists |
| KR20210145787A (ko) | 2019-04-02 | 2021-12-02 | 알리고스 테라퓨틱스 인코포레이티드 | Prmt5를 표적으로 하는 화합물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2048109B1 (es) * | 1992-07-20 | 1994-12-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. |
| EP0626373B1 (en) * | 1993-05-26 | 1998-12-23 | Sumitomo Pharmaceuticals Company, Limited | Quinazolinone derivatives |
| US6211199B1 (en) * | 1995-11-17 | 2001-04-03 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases |
| AU2001292730A1 (en) * | 2000-09-20 | 2002-04-02 | Schering Corporation | Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists |
| ATE529112T1 (de) * | 2002-04-18 | 2011-11-15 | Schering Corp | 1-(4-piperidinyl)benzimidazolone als histamin h3 antagonisten |
-
2003
- 2003-04-16 RU RU2004133764/04A patent/RU2323935C2/ru not_active IP Right Cessation
- 2003-04-16 AR AR20030101340A patent/AR040405A1/es active IP Right Grant
- 2003-04-16 JP JP2003585719A patent/JP4384918B2/ja not_active Expired - Lifetime
- 2003-04-16 PL PL03373889A patent/PL373889A1/xx not_active Application Discontinuation
- 2003-04-16 SI SI200331201T patent/SI1499316T1/sl unknown
- 2003-04-16 WO PCT/US2003/011672 patent/WO2003088967A1/en active IP Right Grant
- 2003-04-16 MX MXPA04010173A patent/MXPA04010173A/es active IP Right Grant
- 2003-04-16 ES ES03719766T patent/ES2301791T3/es not_active Expired - Lifetime
- 2003-04-16 NZ NZ535763A patent/NZ535763A/en not_active IP Right Cessation
- 2003-04-16 EP EP03719766A patent/EP1499316B1/en not_active Expired - Lifetime
- 2003-04-16 DK DK03719766T patent/DK1499316T3/da active
- 2003-04-16 PT PT03719766T patent/PT1499316E/pt unknown
- 2003-04-16 CA CA002481940A patent/CA2481940A1/en not_active Abandoned
- 2003-04-16 CN CNB038137798A patent/CN100522166C/zh not_active Expired - Fee Related
- 2003-04-16 DE DE60319813T patent/DE60319813T2/de not_active Expired - Lifetime
- 2003-04-16 AU AU2003223627A patent/AU2003223627B2/en not_active Ceased
- 2003-04-16 PE PE2003000390A patent/PE20040684A1/es not_active Application Discontinuation
- 2003-04-16 BR BR0309348-4A patent/BR0309348A/pt not_active IP Right Cessation
- 2003-04-16 AT AT03719766T patent/ATE389406T1/de not_active IP Right Cessation
- 2003-04-16 KR KR1020047016508A patent/KR100827470B1/ko not_active IP Right Cessation
- 2003-04-17 TW TW092108912A patent/TW200306183A/zh unknown
-
2004
- 2004-10-04 ZA ZA200407984A patent/ZA200407984B/xx unknown
- 2004-10-14 IL IL164584A patent/IL164584A/en not_active IP Right Cessation
- 2004-10-15 EC EC2004005367A patent/ECSP045367A/es unknown
- 2004-11-17 NO NO20045002A patent/NO20045002L/no unknown
-
2005
- 2005-01-26 HK HK05100695A patent/HK1067981A1/xx not_active IP Right Cessation
-
2008
- 2008-06-09 CY CY20081100604T patent/CY1110363T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110363T1 (el) | Παραγωγα (1-4-πιπεριδινυλ)βενζιμιδαζολιου χρησιμα σαν ανταγωνιστες η3 ισταμινης | |
| CY1105986T1 (el) | Παραγωγα ινδολιου χρησιμα ως ανταγωνιστες η3 ισταμινης | |
| CY1109401T1 (el) | Παραγωγα πιπεριδινης ως ανταγωνιστες του δεκτου nmda | |
| CY1105621T1 (el) | Νεα ετεροκυκλικα παραγωγα φθορογλυκοζιτου, φαρμακα που περιεχουν τις ενωσεις αυτες και η χρηση τους | |
| CY1108754T1 (el) | Νεα παραγωγα θειοφαινογλυκοσιδης, μεθοδος για την παρασκευη τους, φαρμακα περιεχοντα αυτες τις ενωσεις και η χρηση τους | |
| MY132566A (en) | Benzimidazolone histamine h3 antagonists | |
| CY1116103T1 (el) | Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης | |
| CY1118128T1 (el) | Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2 | |
| CY1113450T1 (el) | Διαμινοπυριμιδινες ως ρ2χ3 και ρ2χ2/3 ανταγωνιστες | |
| CY1124496T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| CY1114708T1 (el) | Παραγωγα πυραζολο-κιναζολινης, διαδικασια για την παρασκευη τους και η χρηση τους ως αναστολεων κινασης | |
| CY1109677T1 (el) | Παραγωγα κινολινης και χρηση αυτων ως μυκοβακτηριακων αναστολεων | |
| CY1110863T1 (el) | Παραγωγα του 2-(8,9-διοξο-2,6-διαζαδικυκλο (5.2.0)-εννε-1(7)-εν-2-υλ)αλκυλ-φωσφονικου οξεος και η χρηση τους ως ανταγωνιστων του ν-μεθυλ- d-ασπαρτικου (nmda) υποδοχεα | |
| CY1105617T1 (el) | Νεα αρωματικα παραγωγα των φθορογλυκοσιδων, φαρμακα περιεχοντα αυτες τις ενωσεις και η χρηση τους | |
| CY1112286T1 (el) | Παραγωγα πυραζολιου χρησιμα για τη θεραπεια γυναικολογικων ασθενειων | |
| CY1109227T1 (el) | Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων | |
| CY1125016T1 (el) | Διαμορφωτες υποδοχεα πιπεριδινης cxcr7 | |
| CY1106679T1 (el) | Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα | |
| CY1117584T1 (el) | Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1 | |
| CY1105227T1 (el) | Ενωσεις πιπepιδινης ως αντιαλλepγικα | |
| CY1106598T1 (el) | Παραγωγα κινολινης και ισοκινολινης, μεθοδος για την παραγωγη αυτων και χρηση αυτων ως αντιφλεγμονωδη μεσα | |
| CY1109656T1 (el) | Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης | |
| CY1111425T1 (el) | ΠΑΡΑΓΩΓΑ ΤΗΣ ΠΥΡΙΔΟ[2,1-a]-ΙΣΟΚΙΝΟΛΙΝΗΣ ΩΣ DPP-IV ΑΝΑΣΤΟΛΕΙΣ | |
| NO20060664L (no) | N-substituerte benzimidazolyl C-kit inhibitorer | |
| CY1107281T1 (el) | Παραγωγα τροπανιου υποκατεστημενα με ιδιδαζοπυριδινη με ενεργοτητα ανταγωνιστη ccr5 υποδοχεα για τη θεραπεια hiv και φλεγμονης |